The Fund for Elimination of Viral Hepatitis (DBA "EndHep2030") has been launched at the World Hepatitis Summit (November 1-3, 2017. Sao Paulo, Brazil). Conceived as a collaborative funding platform, EndHep2030 was a direct outcome of the International Roundtable Summit of Funding for Elimination of Viral Hepatitis (June 20-21, 2016. Hong Kong, China).
The latest news on the fight to end viral hepatitis.
World Hepatitis Day (WHD) takes place every year on July 28th, bringing the world together under a single theme — to raise awareness of the global burden of viral hepatitis and to influence real change.
The Fund for Elimination of Viral Hepatitis (DBA “EndHep2030”) was conceived as a result of the International Roundtable Summit on Funding for Elimination of Viral Hepatitis (June 20 -21, 2016. Hong Kong, China) organized by ZeShan Foundation in collaboration with the US CDC and World Health Organization.
In June 2016 ZeShan Foundation, in collaboration with the United States Centers for Disease Control and Prevention (US CDC) and the World Health Organization (WHO), convened a meeting designed to stimulate critical thinking and discussion around the establishment of an international funding mechanism to support the implementation of the Global Health Sector Strategy on Viral Hepatitis (“WHO Global Hepatitis Strategy”).
As the hepatitis B virus is widely spread and responsible for considerable morbidity and mortality, WHO recommends vaccination from infancy to reduce acute infection and chronic carriers. However, current subunit vaccines are not 100% efficacious and leave 5–10% of recipients unprotected.
Japanese scientists at the Biomedical Research Institute at the National Institute of Advanced Industrial Science and Technology have created hens that can lay “golden eggs” containing a protein used to treat cancer and hepatitis. These scientists used new genome editing technology to create the hens that can lay multi-million pound golden eggs with high quantities of human interferon beta at a low cost.
HCV is a global and national concern with treatments being easily available for free, or at subsidized rates, across the country and in neighbouring States like Manipur, Meghalaya and Mizoram. However in Nagaland, HCV treatment and testing facilities are still not accessible or available for the general population.
“Setting targets under the National Viral Hepatitis Control Programme, the Indian health ministry had pledged to achieve 100% usage of ingineered safety devices to curtail injection related infections,” said Dr Chandrakant Lahariya, WHO-India.